Adenocarcinoma of the lung is the most common type of lung cancer, accounting for about 45% of all lung cancer cases in the United States. It begins in the cells that line the lung’s tiny air sacs, the ones responsible for producing mucus and other substances. Unlike some other lung cancers that grow near the central airways, adenocarcinoma typically develops in the outer (peripheral) regions of the lungs, which has important implications for how it’s detected, how symptoms appear, and how it’s treated.
Adenocarcinoma falls under the broader category of non-small cell lung cancer (NSCLC), which also includes squamous cell carcinoma (25% of lung cancers) and large cell carcinoma (10%). The distinction matters because each subtype behaves differently and responds to different treatments.
Why Adenocarcinoma Develops in Non-Smokers Too
Smoking is the leading risk factor for all lung cancers, but adenocarcinoma stands out as the subtype most likely to appear in people who have never smoked. Between 50% and 60% of lung cancers found in never-smokers are adenocarcinomas. This doesn’t mean smoking isn’t a factor. It absolutely is. But it means other causes play a significant role.
Secondhand smoke, radon gas (which can accumulate in homes), air pollution, diesel exhaust, and workplace exposure to asbestos, arsenic, silica, or chromium all raise the risk. A personal or family history of lung cancer is another contributor that can’t be changed. People who develop adenocarcinoma without a smoking history are more likely to carry specific DNA mutations, particularly in the EGFR gene, that drive tumor growth. In a large study of over 3,000 lung adenocarcinomas, EGFR mutations appeared in 43% of never-smokers compared to 11% of smokers. KRAS mutations, another common driver, showed the opposite pattern: 34% in smokers versus 6% in never-smokers.
Symptoms and Why They Often Appear Late
Because adenocarcinoma tends to grow in the outer edges of the lungs, away from the major airways, it can grow for a while before causing noticeable symptoms. By the time symptoms appear, the tumor may be fairly advanced. Common signs include a persistent cough that worsens over time, chest pain that gets worse with deep breathing or coughing, shortness of breath, coughing up blood or rust-colored mucus, and unexplained weight loss or fatigue.
Some symptoms are less obvious. Recurring lung infections like pneumonia or bronchitis that keep coming back can signal an underlying tumor. Swelling of the neck and face, hoarseness, and a widening of the fingertips (called clubbing) are also associated with lung cancer. If the cancer has spread beyond the lungs, it can cause bone pain, headaches, dizziness, numbness in the arms or legs, balance problems, or yellowing of the skin and eyes.
How It’s Diagnosed
For many people, the first hint of lung cancer shows up on a chest X-ray or CT scan, sometimes done for an unrelated reason. If something suspicious appears, further imaging with a PET/CT scan or MRI helps clarify the size and spread of the abnormality.
A biopsy is the only way to confirm a diagnosis. Several approaches exist depending on where the tumor sits. Bronchoscopy uses a small camera threaded through the airways and works best for tumors near or just outside the central airway passages. For tumors in the outer lung that a bronchoscope can’t reach, a needle biopsy through the chest wall (guided by imaging) is the typical alternative. Endobronchial ultrasound (EBUS) combines a camera with ultrasound to sample lymph nodes around the lungs. In some cases, surgery is needed to get a tissue sample when other methods can’t reach the growth.
Genetic Testing of the Tumor
Once cancer is confirmed, the biopsy sample goes through genetic profiling. This step is critical for adenocarcinoma because treatment decisions depend heavily on which mutations are driving the tumor. Labs test for changes in genes like EGFR, KRAS, and ALK, along with less common alterations in BRAF, HER2, NTRK, MET, RET, and ROS1. These tests can also be done through a liquid biopsy, which looks for tumor DNA circulating in the blood. The results determine whether you’re a candidate for targeted therapies, which can be far more effective than standard chemotherapy for tumors with specific mutations.
Treatment Options
Treatment for lung adenocarcinoma depends on the stage at diagnosis and the tumor’s genetic profile. Early-stage cancers that haven’t spread beyond the lung are typically treated with surgery to remove the tumor, sometimes followed by additional therapy to reduce the chance of recurrence. For example, patients with early-stage tumors carrying an ALK gene rearrangement may receive a targeted drug after surgery to lower the risk of the cancer returning.
For advanced or metastatic adenocarcinoma, the genetic testing results shape the entire treatment plan. Tumors with EGFR mutations can be treated with drugs that specifically block the signals those mutations send to fuel cancer growth. ALK-rearranged tumors have their own class of targeted drugs, with newer-generation options that are more effective and can also reach cancer that has spread to the brain. Tumors with KRAS, RET, ROS1, MET, or other actionable mutations each have corresponding targeted treatments.
Immunotherapy, which helps your immune system recognize and attack cancer cells, is a major part of treatment for adenocarcinomas that lack targetable mutations. It’s often combined with chemotherapy as a first-line approach. Traditional chemotherapy remains part of the treatment landscape as well, sometimes paired with newer agents. One combination approach uses a lab-made antibody that targets two proteins on cancer cells (EGFR and MET) alongside chemotherapy.
The frequent discovery of new drug approvals and combinations means treatment guidelines are updated multiple times per year. What’s available today may be substantially different from what was standard even a year ago.
Survival Rates by Stage
The five-year relative survival rate for lung cancer varies dramatically depending on how far the cancer has spread at the time of diagnosis. Based on data from 2016 to 2022, people with localized disease (confined to the lung) have a 65.5% five-year survival rate. When the cancer has spread to nearby lymph nodes (regional stage), that drops to 38.2%. For distant or metastatic disease, the five-year survival rate is 10.5%.
These numbers represent averages across all lung cancers and all patients. Individual outcomes depend on factors like the specific genetic mutations involved, overall health, age, and how well the cancer responds to targeted therapy or immunotherapy. The survival landscape has improved notably in recent years as targeted treatments and immunotherapy have become standard.
Screening for Early Detection
Because adenocarcinoma often causes no symptoms until it has advanced, screening plays an important role in catching it early. The U.S. Preventive Services Task Force recommends annual low-dose CT scans for adults aged 50 to 80 who have a 20 pack-year smoking history and either still smoke or quit within the past 15 years. A pack-year equals smoking one pack per day for one year, so someone who smoked two packs a day for 10 years would meet the threshold.
Screening stops making sense once someone has been smoke-free for 15 years or has a health condition that would prevent them from undergoing treatment if cancer were found. These guidelines don’t currently cover never-smokers, even though adenocarcinoma is the most common lung cancer in that group. Lowering your risk if you’ve never smoked means testing your home for radon, avoiding secondhand smoke and air pollution, and being aware of occupational exposures to known carcinogens like asbestos and arsenic.
What Makes Adenocarcinoma Biologically Distinct
One of the defining characteristics of lung adenocarcinoma is its genetic and structural complexity. Under a microscope, most adenocarcinomas are a mix of different growth patterns rather than a single uniform type. A tumor might contain areas that look glandular alongside areas that appear solid, papillary, or flat. This internal diversity, or heterogeneity, is one reason biopsies and thorough genetic testing are so important. A small sample might not capture the full picture of what’s driving the cancer.
This heterogeneity also helps explain why adenocarcinoma responds so differently from patient to patient. Two people with the same stage of disease can have very different outcomes depending on which mutations are present and how varied the tumor’s internal architecture is. It’s the reason personalized treatment, guided by molecular profiling rather than a one-size-fits-all approach, has become the standard of care.